

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

April 18, 2022

ISSUE No.

1648

IN THIS ISSUE

Expanded Heart Failure Indication for Empagliflozin (*Jardiance*).....p 57

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 64 (Issue 1648)

April 18, 2022

Take CME Exams

IN BRIEF

Expanded Heart Failure Indication for Empagliflozin (*Jardiance*)

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (*Jardiance* – Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF; LVEF \leq 40%), regardless of whether or not they have type 2 diabetes.¹ The indication has now been expanded to include patients with HF with any ejection fraction. Empagliflozin is the first SGLT2 inhibitor to be approved in the US for this indication.

SGLT2 INHIBITORS AND HF – All currently available SGLT2 inhibitors have been shown to reduce the risk of hospitalization for HF by ~30% in patients with type 2 diabetes. The SGLT2 inhibitor dapagliflozin (*Farxiga*) was approved in 2020 to reduce the risk of hospitalization for HF and cardiovascular death in patients with HFrEF, with or without diabetes.² Canagliflozin (*Invokana*) and ertugliflozin (*Steglatro*), the other two SGLT2 inhibitors available in the US, do not have a HF indication.

CLINICAL STUDIES – FDA approval for the expanded indication was based on the results of a double-blind trial (EMPEROR-Preserved) in 5988 patients with NYHA class II-IV HF and a LVEF $>$ 40% who were randomized to receive empagliflozin 10 mg or placebo once daily in addition to standard treatment for heart failure with preserved ejection fraction (HFpEF). About 50% of the patients had type 2 diabetes. Over a median follow-up of 26.2 months, the incidence of a composite of hospitalization for HF or cardiovascular

death, the primary endpoint, was statistically significantly lower in the empagliflozin group than in the placebo group (13.8% vs 17.1%; 6.9 vs 8.7 events per 100 patient-years), primarily because of a lower risk of hospitalization for HF. Relative outcomes were similar in patients with or without type 2 diabetes. The number of patients needed to be treated with empagliflozin to prevent one primary outcome event was 31 (95% CI 20-69).³

DOSAGE AND COST – The recommended dosage of empagliflozin for all indications is 10 mg once daily. For patients with type 2 diabetes who need additional glycemic control, the dose can be increased to 25 mg. A 30-day supply of *Jardiance* costs \$570.50.⁴

CONCLUSION – Addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (*Jardiance*) to standard treatment for heart failure with preserved ejection fraction reduced the composite risk of hospitalization for heart failure or cardiovascular death in patients with an LVEF $>$ 40%, with or without type 2 diabetes. Empagliflozin is the first SGLT2 inhibitor to be FDA-approved for use in patients with heart failure with any ejection fraction. ■

1. Empagliflozin (*Jardiance*) for heart failure with reduced ejection fraction. *Med Lett Drugs Ther* 2021; 63:171.
2. Dapagliflozin (*Farxiga*) – a new indication for heart failure. *Med Lett Drugs Ther* 2020; 62:102.
3. SD Anker et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021; 385:1451.
4. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource@ Monthly. March 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-2859

The
 Medical
 Letter